Update on new cGMP-4 facility at Dewas

Greenfield CommissionedCapex & Operations View source PDF Explain this filing

NAVINFLUOR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹4860.00

prior close

₹4780.20

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%-1.4% vs market

Specialty Chemicals peers, median of 85sector-0.7%-1.3% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Smallcap 250 and 1.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

+0.0

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.7-1.4-0.7-1.3

Next day

-3.9-0.4-3.5-0.7-3.2

-4.0-0.3-3.8-0.9-3.1

-1.9+0.0-1.9-0.8-1.1

-2.5+0.7-3.1+0.0-2.5

-2.1+0.7-2.7+0.0-2.1

-1.7+1.6-3.4-0.8-1.0

15d

-2.4+0.4-2.8-1.8-0.6

-6.0+0.3-6.3-3.3-2.7

+24.7+2.0+22.7-5.5+30.2

+18.0-2.3+20.4-10.9+28.9

UpDownMarket · Nifty Smallcap 250Sector · Specialty Chemicals peers, median of 85Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Navin Fluorine International has shared an update on its new cGMP-4 manufacturing facility at Dewas. The facility is expected to support the company's pharmaceutical and chemical manufacturing capabilities, adhering to current Good Manufacturing Practice (cGMP) standards. This is part of the company's expansion plans to meet growing demand in regulated markets. Specific timelines, investment details, and production capacity were not disclosed in the headline-level information.

Likely market impact

Positive for shareholders as commissioning of a new cGMP-compliant facility signals capacity expansion and potential revenue growth in the pharmaceutical chemicals segment, though concrete financial details are awaited.